In a note issued Friday, Piper Jaffray said the weakness in Regeneron (NASDAQ:REGN) is a buying opportunity, as the firm sees risks to the company’s alirocumab Phase III program as overblown, with neither Regeneron  (NASDAQ:REGN) or its development partner Sanofi (SNY) having seen any neurocognitive adverse events with the drug. The firm reiterates a Buy rating and $376 price target on shares. Deutsche Bank reports Regeneron … Continue reading BioTech After Hours Active Stocks: Regeneron (NASDAQ:REGN), Ambarella (NASDAQ:AMBA), Progress Software (NASDAQ:PRGS)